ELIAS Animal Health Expands Clinical Trial of Immunotherapy Treatment for Cancer in Dogs
ELIAS Animal Health Expands Clinical Trial of Immunotherapy Treatment for Cancer in Dogs By ELIAS Animal Health Save
OLATHE, Kan., Nov. 12, 2020/ PRNewswire/– ELIAS Animal Health, a clinical phase growth company progressing unique therapies for cancer cells in companion animals, reveals that 10 examination websites across the U.S. are now getting involved in the essential trial of ELIAS cancer cells immunotherapy (ECI ®). This notes an expansion of the research study ELIAS started in May to pursue licensure of ECI treatment combined with surgery as an option to chemotherapy for canines diagnosed with osteosarcoma, a lethal kind of bone cancer.
The geographical locations served by the medical test examination sites consist of Southern California, the Intermountain Region, the Desert Southwest, the Chicago city, North Texas, the Carolinas and also the Mid-Atlantic region, which consists of Southeast Pennsylvania, Virginia and Washington, D.C. ELIAS will certainly proceed recruiting sites to more increase pet dog owner access to the trial. For more information regarding getting involved websites and client eligibility, go to www.eliasanimalhealth.com/eci-osa-04.
The medical trial’s goal is to review the efficiency as well as security of ECI contrasted to the current standard of treatment carboplatin chemotherapy. ECI is a form of immunotherapy that includes dealing with the patient with its very own cancer-specific “killer” T cells.
“As we proceed increasing the test, we are thrilled to evaluate our individualized approach to treating canine osteosarcoma in a bigger populace of dogs,” said Tammie Wahaus, ceo, ELIAS Animal Health.
Veterinarians curious about more info on the scientific program may visit www.eliasanimalhealth.com or contact ELIAS at. Interested capitalists might get in touch with ELIAS at.
About ELIAS Animal Health Based in Olathe, Kansas, ELIAS Animal Health is a clinical biotechnology firm progressing its unique targeted T cell-based immunotherapies for the treatment of canine cancers. The ELIAS cancer immunotherapy is being dispersed to vets under 9 CFR 103.3 as an experimental item. The company’s unique therapeutic method supplies the possibility of improved scientific outcomes and the potential for basically changing the method cancer is treated. For more details, see www.eliasanimalhealth.com. This short article initially ran on curated.tncontentexchange.com.